MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
IPO Year: 2004
Exchange: NASDAQ
Website: mannkindcorp.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $12.00 | Outperform | Mizuho |
| 2/10/2025 | $11.00 | Outperform | Wedbush |
| 12/20/2024 | $9.00 | Overweight | Wells Fargo |
| 12/19/2024 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 9/9/2024 | $7.00 → $8.00 | Outperform | Leerink Partners |
| 6/13/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/10/2023 | $10.00 | Outperform | Wedbush |
| 2/28/2022 | $6.50 → $6.00 | Buy | HC Wainwright & Co. |
8-K - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
144 - MANNKIND CORP (0000899460) (Subject)
10-Q - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
DEFA14A - MANNKIND CORP (0000899460) (Filer)
DEF 14A - MANNKIND CORP (0000899460) (Filer)
S-3ASR - MANNKIND CORP (0000899460) (Filer)
10-K - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00
Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00
Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00
RBC Capital Mkts upgraded Mannkind from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Leerink Partners resumed coverage of Mannkind with a rating of Outperform and set a new price target of $8.00 from $7.00 previously
Rodman & Renshaw initiated coverage of Mannkind with a rating of Buy and set a new price target of $8.00
Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage of MannKind with a rating of Buy and set a new price target of $6.00 from $6.50 previously
RBC Capital initiated coverage of MannKind with a rating of Sector Perform and set a new price target of $5.00
SVB Leerink reiterated coverage of MannKind with a rating of Outperform and set a new price target of $5.00 from $3.00 previously
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4/A - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)